ライフサイエンスコーパス: surrogate marker

1 , 0.8% minor errors) using micafungin as the surrogate marker.

2 unohistochemistry could serve as a potential surrogate marker.

3 yellow fluorescent protein (YFP-53BP1) as a surrogate marker.

4 d for future research that evaluates or uses surrogate markers.

5 he development and interpretation of vaccine surrogate markers.

6 ng process in terms of histology and certain surrogate markers.

7 naling, suggesting the peptides may serve as surrogate markers.

8 e were seen for 1 of 23 participant-reported surrogate markers, 2 of 25 visual spatial tests, and 2 o

9 % minor errors [M]) using fluconazole as the surrogate marker and 97.7% (0.3% VME 0.1% ME, and 1.9% M

10 nd cytometric bead array, formed an in vitro surrogate marker and correlate of the in vivo host immun

11 cer undergoing radical resection is an early surrogate marker and correlate to oncologic outcomes.

12 ession of eIF3I in HCC is oncogenic and is a surrogate marker and therapeutic target for treatment wi

13 cle, we examine the challenges of evaluating surrogate markers and describe the framework proposed in

14 Successful co-development of neuroimaging surrogate markers and preventive treatments might eventu

15 nsitivity troponin T (hs-TnT) can be used as surrogate markers and whether genetic variability in ger

16 However, these surrogate markers are not entirely reliable and combinat

17 Many surrogate markers are used, such as documenting evidence

18 The serum sensitivity of each surrogate-marker assay was reduced in animals treated wi

19 We present case studies of 2 well-accepted surrogate markers [blood pressure within sodium intake a

20 nd monitored their fate by X-Gal staining, a surrogate marker coexpressed with the K-Ras(G12V) oncopr

21 FC as a surrogate marker could be used to validate risk factors

22 a genome-wide level by using common promoter surrogate markers (e.g., histone modifications) and were

23 uced intrapatient variability of Tac Cmin, a surrogate marker for 24-hour drug exposure (AUC0-24), ha

24 uced intrapatient variability of Tac Cmin, a surrogate marker for 24-hour drug exposure (AUC0-24), ha

25 otein kinase (DNA-PK) threonine 2609 foci, a surrogate marker for activated nonhomologous end-joining

26 phasizes the potential for DTC analysis as a surrogate marker for adjuvant treatment effect in breast

27 terventions that reduced alert quantity as a surrogate marker for alert fatigue.

28 ential biomarker for tumor progression and a surrogate marker for allosteric RAF blockade.

29 also has many favorable characteristics as a surrogate marker for antigen-specific activation of huma

30 nction, and conduit dilator capacity (DC), a surrogate marker for arterial remodelling, in the brachi

31 ystolic, and mean arterial blood pressure, a surrogate marker for arterial stiffness.

32 erebrospinal fluid (CSF) tau is an excellent surrogate marker for assessing neuropathological changes

33 ity at FDG PET and may be useful as an early surrogate marker for assessing treatment response.

34 samples with raised osmolality and copeptin (surrogate marker for AVP).

35 amples with raised osmolality or copeptin (a surrogate marker for AVP).

36 Early neuroimaging may provide a surrogate marker for brain development and outcome after

37 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation.

38 occurring inhibitor of angiogenesis and as a surrogate marker for cancer progression; it is also link

39 ells expressing both a caspase-3 sensor as a surrogate marker for caspase-3 activation and Renilla lu

40 ctivation and Renilla luciferase (Rluc) as a surrogate marker for cell viability were established and

41 ol/L), and total-to-ionized calcium ratio, a surrogate marker for citratemia, was unchanged.

42 o measuring myocardial flow reserve (MFR), a surrogate marker for coronary vascular health.

43 light chain (NF-L) could be a more practical surrogate marker for disease staging in amyotrophic late

44 tted from the emergency department acts as a surrogate marker for early aggressive care in the manage

45 y correlated with HER2 status, possibly as a surrogate marker for ER status and a predictor for tamox

46 bacterial clearance could serve as a timely surrogate marker for evaluating the appropriateness of a

47 matory functional test for Glut1 DS and as a surrogate marker for GLUT1 haploinsufficiency.

48 It has the potential to be used as a surrogate marker for GS and predict LNI.

49 p16 is used as a surrogate marker for HPV infection.

50 Although p16 may be used as a surrogate marker for HR-HPV status in other tissue sites

51 PtdCho-DHA may be useful as a surrogate marker for in vivo hepatic PEMT activity in hu

52 monitoring the C. elegans exometabolism as a surrogate marker for internal metabolic events.

53 a circulating fragment of SOGA, providing a surrogate marker for intracellular SOGA levels.

54 flow (RPF), and filtration fraction (FF) (a surrogate marker for intraglomerular pressure) were meas

55 Measurement of CFIMs may be a surrogate marker for IPMN progression and allow for the

56 data suggest body curvature may be used as a surrogate marker for kidney cyst formation in large-scal

57 Pro-substance P (ProSP) is a stable surrogate marker for labile substance P, which has pro-i

58 stion the validity of relapse frequency as a surrogate marker for late disability.

59 4(+) T cell counts and either age (used as a surrogate marker for length of infection) or viremia.

60 s the importance of MRD-negative status as a surrogate marker for longer PFS in clinical studies to a

61 a clinical sign of intestinal failure and a surrogate marker for markedly increased risk of mortalit

62 Because weight is a surrogate marker for metabolic demands, we looked at the

63 Metastasis size serves as a surrogate marker for metastatic activity of colorectal l

64 T1 contrast ratios may provide a noninvasive surrogate marker for monitoring this loss in MS patients

65 nce relative to linear RNAs can be used as a surrogate marker for mRNA stability in the absence of tr

66 Since the catatonic syndrome is likely a surrogate marker for other executive function defects, w

67 recent metaanalysis could validate pCR as a surrogate marker for patient outcomes only in aggressive

68 e or both of these agents may be useful as a surrogate marker for posaconazole susceptibility.

69 we propose initial steroid sensitivity as a surrogate marker for post-transplant recurrence.

70 on, these data implicate Pin1 as a potential surrogate marker for predicting outcome of ERalpha-posit

71 Peritransplant ALC is a novel and useful surrogate marker for prediction of HCV recurrence and pa

72 se, we asked whether GFAP might be used as a surrogate marker for prions.

73 lidate a specific amount of weight loss as a surrogate marker for protection.

74 believe that FC is likely to prove a useful surrogate marker for risk of developing CD.

75 thens the basis for MRI providing an in vivo surrogate marker for structural and behavioural deficits

76 eptomeningeal enhancement may prove a useful surrogate marker for such pathology, perhaps improving o

77 pressed higher levels of cell surface CD5, a surrogate marker for TCR avidity for self-pMHC, as compa

78 uld be used as a simple, rapid, and reliable surrogate marker for the activities of MMPs in growing b

79 itude of muscle contractions, representing a surrogate marker for the characteristic loss of muscle s

80 ggest that [F-18]-AV-1451 holds promise as a surrogate marker for the detection of brain tau patholog

81 t the degree of hypointensity can serve as a surrogate marker for the efficacy of tumor vaccination.

82 5-HTP uptake and retention in pancreas, as a surrogate marker for the endogenous islet mass.

83 11)C]5-HTP retention is a useful noninvasive surrogate marker for the human endocrine pancreas.

84 Blood albumin leakage could be a surrogate marker for the in vivo evaluation of intervent

85 olute lymphocyte count (ALC) is considered a surrogate marker for the level of immunosuppression and

86 olute lymphocyte count (ALC) is considered a surrogate marker for the level of immunosuppression and

87 an fluorescence intensity was not a suitable surrogate marker for the prediction of complement bindin

88 Micafungin may serve as an acceptable surrogate marker for the prediction of susceptibility an

89 evel of total alpha-synuclein could act as a surrogate marker for the progression of PD.

90 eperfusion treatment but rather represents a surrogate marker for the severity of risk and injury to

91 hinococcosis (AE) and has been proposed as a surrogate marker for therapeutic decisions on structured

92 gest that cortical thickness may be a useful surrogate marker for these types of dementia.

93 me for orthotopic liver transplantation as a surrogate marker for this reluctance.

94 We measured TNF receptor 1 (TNFR1) as a surrogate marker for TNF-alpha in 438 recipients of myel

95 ribosomal protein S6 (P-S6) was defined as a surrogate marker for TOR-dependent anabolic activity in

96 densation product of all-trans-retinal and a surrogate marker for toxic retinoids.

97 In the present study we show that PrP(sc), a surrogate marker for TSE infection, can be detected in c

98 salpinx in women and mice has been used as a surrogate marker for tubal infertility, the medical rele

99 FDG PET could be used as a noninvasive surrogate marker for tumor growth and viability in this

100 S100A9 could serve as a surrogate marker for tumor immune crosstalk as a functio

101 the infection, its treatment, or could be a surrogate marker for underlying immune defects.

102 trophil clusters in the renal allograft is a surrogate marker for urinary tract infection (UTI).

103 ival within chicken (HD-11) macrophages as a surrogate marker for virulence.

104 Surrogate markers for 25(OH)D concentrations, although s

105 While brain volume changes are used as surrogate markers for Alzheimer disease neuropathology i

106 thrombosis, despite the lack of evidence of surrogate markers for atherosclerosis in primary APS.

107 ia and emphasize the critical need to define surrogate markers for correlates of protection, apart fr

108 on, which circumvents limitations of current surrogate markers for defining the repertoire of respond

109 and CRISP2 DMRs hold promise as novel blood surrogate markers for early risk stratification and CVD

110 for disease development and progression, and surrogate markers for efficacy end points in clinical dr

111 binding MR contrast agent and may be used as surrogate markers for evaluating the healing response of

112 The availability of surrogate markers for functional vascular proteins, such

113 ereas serum levels of phytosterols represent surrogate markers for intestinal cholesterol absorption,

114 r arterial blood gas monitoring, noninvasive surrogate markers for lung disease severity are needed t

115 retina is an attractive source of potential surrogate markers for paediatric cerebral malaria becaus

116 id inflammatory markers (CFIMs), as possible surrogate markers for parenchymal inflammation.

117 magnitude of EBVd were assessed as potential surrogate markers for the occurrence of late adverse eve

118 verity markers, which use SpO2, are adequate surrogate markers for those that use PaO2 in children wi

119 opment of TS vaccines for human use, suggest surrogate markers for use in future human vaccine trials

120 al progenitor cell (EPC) counts are proposed surrogate markers for vascular function and cardiovascul

121 r potential usefulness in the development of surrogate markers for vector delivery during the first w

122 It is unclear how well surrogate markers for vitamin D exposure (eg, oral intak

123 Improvement in surrogate markers has not necessarily translated into be

124 lity may not be a feasible endpoint and many surrogate markers have been explored, ranging from pulmo

125 Although surrogate markers have been identified and compelling CS

126 effective in presumptive PVAN as defined by surrogate markers (i.e., high BK virus viremia).

127 lcitonin (PCT) has been shown to be a useful surrogate marker in identifying patients with various ba

128 of transformation, and, more recently, as a surrogate marker in new drug development.

129 At present, the suitability of CIMT as a surrogate marker in trials of cardiovascular therapies t

130 says and breath tests could become important surrogate markers in early bactericidal activity (EBA) s

131 CECs and CPCs are currently studied as surrogate markers in patients for more than a dozen path

132 ct measure of insulin secretion with fasting surrogate markers in relation to glucose tolerance statu

133 s an alternative or together with HbA1c as a surrogate marker indicator for glycemic control.

134 The correlation of PD with ASVD outcomes and surrogate markers is discussed, as well as the correlati

135 ve model with the use of different vitamin D surrogate markers (latitude of residence, mean annual re

136 the pathogenesis, genetics and biomarkers or surrogate markers may be useful for the diagnosis and id

137 Furthermore, the use of surrogate markers may misrepresent the MAIT cell populat

138 Surrogate markers may provide insight into pathogenesis

139 arms, ICR (compared with CR) seemed to be a surrogate marker of a greater burden of anatomical coron

140 The latter may be a surrogate marker of abnormal heart rate variability in C

141 cal HFOs, such as FR, may provide a reliable surrogate marker of abnormal neuronal excitability in hi

142 CCA test, which we consider to be a suitable surrogate marker of active infection.

143 Moreover, sputum EPX was a surrogate marker of airway eosinophilia in other patient

144 flammation over time, PET could be used as a surrogate marker of antiatheroma drug efficacy.

145 noninvasive imaging technique that detects a surrogate marker of apoptosis may help characterize the

146 ter of >/=40 from month 13 to month 25) as a surrogate marker of asymptomatic infection in the vaccin

147 easing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes corr

148 or partially the IGFBP and vWC domains as a surrogate marker of CCN1 activity in PDR distinguishing

149 significantly correlated with 2-week Ki67, a surrogate marker of clinical outcome (r = -0.179; P = .0

150 occurring early in treatment may serve as a surrogate marker of clonal suppression and, therefore, m

151 t measure of subclinical atherosclerosis and surrogate marker of coronary heart disease.

152 ilure strongly reduce midazolam clearance, a surrogate marker of CYP3A-mediated drug metabolism, in c

153 Left atrial size is a surrogate marker of diastolic function.

154 c magnetic resonance have been shown to be a surrogate marker of diffuse myocardial fibrosis.

155 WM pathogenesis, along with its utility as a surrogate marker of disease and a target in the treatmen

156 s that the PBMC transcriptome may serve as a surrogate marker of DOX-induced cardiotoxicity.

157 n selecting patients and when using MRI as a surrogate marker of efficacy.

158 ventricular conduction delay rather than the surrogate marker of electrical delay demonstrated by pro

159 hosterol-to-cholesterol ratio (L:C ratio), a surrogate marker of endogenous cholesterol synthesis, se

160 Microparticles (MPs) have emerged as a surrogate marker of endothelial dysfunction and cardiova

161 endothelium-dependent vasodilation and is a surrogate marker of endothelial function and NO bioavail

162 a valid, reliable, repeatable, and specific surrogate marker of eosinophils and/or eosinophil degran

163 tion and fatty liver index (FLI; a validated surrogate marker of fatty liver), as well as the associa

164 alactomannan assay (GM), a non-culture-based surrogate marker of fungal infection, is widely used in

165 ed low pepsinogen 1 to 2 (PEP1:2) ratio as a surrogate marker of gastric atrophy.

166 her whole retinal thickness can be used as a surrogate marker of glaucomatous change.

167 ve shown that the SNR test provides a useful surrogate marker of hearing.

168 ft ventricular ejection fraction (LVEF) is a surrogate marker of heart failure (HF) status and associ

169 nsferase-to-platelet ratio index (APRI) as a surrogate marker of hepatic fibrosis to characterize liv

170 perioperative aspartate aminotransferase, a surrogate marker of hepatic ischemia reperfusion injury,

171 Expression of p16 is used as a surrogate marker of HPV infection.

172 gher residual SYNTAX Score was shown to be a surrogate marker of increasing clinical comorbidity and

173 RBC aggregation is a surrogate marker of inflammation that can be quantified

174 ole retinal thickness in the rat as a useful surrogate marker of inner and outer retinal changes.

175 elationship between body mass index (BMI), a surrogate marker of insulin resistance, and iron burden

176 We analyzed urinary dd-cfDNA as a surrogate marker of kidney transplant injury.

177 Low serum creatinine is a better surrogate marker of low muscle mass than a low body mass

178 every measure that we commonly use is only a surrogate marker of LV function due to the fact that it

179 DC) at low- and medium-b-value regimens as a surrogate marker of microcirculation, to study its corre

180 d antibody-in-lymphocyte supernatant (ALS, a surrogate marker of mucosal immune responses) from patie

181 ons, making this neuroinflammation process a surrogate marker of neuronal dysfunction.

182 elin-specific CD4 T cells expressing CD56, a surrogate marker of NK cells, were shown to be cytotoxic

183 Although p16 protein expression, a surrogate marker of oncogenic human papillomavirus (HPV)

184 tracerebral haemorrhage, and may be a useful surrogate marker of ongoing ischaemic injury from small-

185 gm is lacking, the use of this paradigm as a surrogate marker of outcome is limited.

186 tes that the expression of p53R172H can be a surrogate marker of p53 gene transcription.

187 er(916), a modification frequently used as a surrogate marker of PKD1 activity.

188 carotid atheroma in vivo and hence may be a surrogate marker of plaque inflammation.

189 d related cancers, using FLT-PET as an early surrogate marker of response.

190 n-binding contrast agent, gadofosveset, is a surrogate marker of rupture-prone atherosclerotic plaque

191 apid noninvasive technique, may be used as a surrogate marker of SFN.

192 an indicator of diastolic dysfunction and a surrogate marker of significant left to right shunts.

193 ce is a crude explanatory variable that is a surrogate marker of socioeconomic status, education, and

194 (ADSCs) undergoing apoptosis can serve as a surrogate marker of stem cell death.

195 Tumor response is considered a surrogate marker of survival.

196 Circulating CLA(+) T cells may be a reliable surrogate marker of the inflammatory events occurring in

197 ein-Barr virus (EBV) DNAemia (EBVd) may be a surrogate marker of the net state of immunosuppression a

198 IP-10 thus may be a surrogate marker of the rate of intracellular viral repl

199 ot only a signpost of cholestasis but also a surrogate marker of the severity of primary biliary cirr

200 Using SOD2 as a surrogate marker of the UPR(mt), we found that in primar

201 released by these cells may be a measurable surrogate marker of this progression.

202 f allergen immunotherapy and may be a useful surrogate marker of treatment efficacy in future studies

203 igh-avidity Melan-A-specific clonotypes as a surrogate marker of treatment efficacy.

204 orrelation with PSA levels (P < 0.0001) as a surrogate marker of tumor burden, whereas SUVmax (P = 0.

205 colony-forming unit osteoblasts (CFU-Os), a surrogate marker of undifferentiated mesenchymal cells a

206 tokines in vaginal secretions may serve as a surrogate marker of unwanted inflammatory reaction to mi

207 DRIL is a robust and easily obtained surrogate marker of VA in participants with current or r

208 diated protection and may represent a useful surrogate marker of vaccine efficacy without the need fo

209 Circumpapillary RNFL is a surrogate marker of vision and could be helpful in makin

210 yer (RNFL) thickness have been proposed as a surrogate marker of vision but this technique is also li

211 ith vision testing, HH-OCT measures may be a surrogate marker of vision.

212 were used to validate salivary VZV DNA as a surrogate marker of VZV reactivation and then to determi

213 to be associated with T1 relaxation times, a surrogate marker of water content, but not with GABAA re

214 ions to the public social security system, a surrogate marker of work rehabilitation.

215 3S/C33S) mice as determined from analyses of surrogate markers of active TGF-beta, such as P-Smad2, C

216 The search for valid surrogate markers of arterial vascular inflammation led

217 afor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to th

218 tween serum micronutrient concentrations and surrogate markers of atherosclerosis in a cohort of HIV-

219 though quantified decoy cells are acceptable surrogate markers of BK viral replication with unexcepti

220 DED and ePiB, respectively) were compared as surrogate markers of brain perfusion, and the extent to

221 , as markers of exposure as well as putative surrogate markers of cancer outcome.

222 t on cIMT and little or no effect on several surrogate markers of cardiovascular disease in non-diabe

223 e reduction, weight loss, and improvement in surrogate markers of cardiovascular disease.

224 Recent evidence has shown that surrogate markers of cardiovascular risk, including symp

225 ation of atherogenic risk factors, including surrogate markers of carotid and coronary atherosclerosi

226 es, such as alpha/delta frequency ratio, are surrogate markers of cerebral ischemia.

227 Measurements of serum surrogate markers of cholesterol absorption (plant stero

228 In cholesterol stone group, surrogate markers of cholesterol synthesis in serum (e.g

229 Surrogate markers of cholesterol synthesis in serum (squ

230 Using expression of optimal surrogate markers of co-stimulation/exhaustion signature

231 Therefore, Vbeta expansions can serve as surrogate markers of CTL clonality to assess clonal kine

232 ls from uninfected animals, but importantly, surrogate markers of cytotoxicity in infected macaques w

233 reduces allergic sensitization and improves surrogate markers of disease.

234 breaks and prolonged phosphorylation of the surrogate markers of DNA damage H2AX, ataxia telangiecta

235 ected imprinted genes may therefore serve as surrogate markers of DNA methylation in cancer tissue.

236 Thus, as assessed by these surrogate markers of efficacy, NK1R antagonism warrants

237 in view of the absence of easily measurable surrogate markers of efficacy.

238 requires reliable assays of HDL function and surrogate markers of efficacy.

239 rculating endothelial cells (CECs) represent surrogate markers of endothelial damage.

240 ajor limitation of this study was the use of surrogate markers of frailty and comorbid conditions to

241 o-ethyl)-l-tyrosine ((18)F-FET) were used as surrogate markers of glucose utilization, proliferative

242 dothelial cell therapy showed mean levels of surrogate markers of hepatobiliary injury that were cons

243 Given their utility as surrogate markers of HIV disease progression, this sugge

244 We hypothesized that surrogate markers of host immune response may predict su

245 EBVd within the first 6 months after SOT are surrogate markers of increased risk of IRAE.

246 t mucosal recurrence after surgery; however, surrogate markers of inflammation, specifically stool la

247 l studies that assessed associations between surrogate markers of innate technical abilities in surgi

248 indications for empirical treatment based on surrogate markers of invasive candidiasis are warranted.

249 contact force, ablation duration, and these surrogate markers of lesion formation may allow us to de

250 TE is one of the best current surrogate markers of liver fibrosis in PBC.

251 chanistic link between fetal environment and surrogate markers of long-term health.

252 levels in circulating immune complexes (IC), surrogate markers of modified LDL, are associated with i

253 s have tended to use biochemical and imaging surrogate markers of NAFLD, such as elevated gamma gluta

254 disease (sCJD) are based on the detection of surrogate markers of neuronal damage such as CSF 14-3-3,

255 cortex showed that JNK inhibition suppressed surrogate markers of neurovascular remodeling, including

256 or reducing or treating adverse effects, and surrogate markers of normal-tissue injury.

257 Many proteins have been proposed to act as surrogate markers of organ damage, yet for many candidat

258 iopoietin-2 release correlated strongly with surrogate markers of organ dysfunction and disease sever

259 ed a significant increase in lesion size and surrogate markers of plaque vulnerability.

260 es of trials of aggressive statin therapy on surrogate markers of progression have shown no benefit f

261 e factor 6 (KLF6) as critical regulators and surrogate markers of prostatic tissue architectures, whi

262 ighlight the limitations of current in vitro surrogate markers of protection, such as cell-based neut

263 peripheral blood mononuclear cells potential surrogate markers of response to therapy.

264 ly that these 2 structural parameters may be surrogate markers of retinal function in the early stage

265 unological and transcriptional signatures as surrogate markers of successful immunotherapy.

266 Therefore, surrogate markers of T cell activation such as CD69, CD4

267 Assessment of surrogate markers of TdP-risk, such as QT-interval prolo

268 ign of embolic protection devices focuses on surrogate markers of the clinical disease, primarily on

269 e (LPR) and exploratory immune monitoring as surrogate markers of therapeutic response.

270 There is a critical need for real time surrogate markers of therapeutic success, to aid in pati

271 tigen (PCNA) and FANCD2 monoubiquitinations (surrogate markers of TLS and FA pathway activation, resp

272 (RNAi)-mediated suppression of ENOX1 impairs surrogate markers of tumor angiogenesis/vasculogenesis,

273 Screening programs using surrogate markers of viral replication are important pre

274 Gene expression of the WNT-pathway surrogate marker osteopontin and the metastasis-associat

275 lysates were digested with proteases, and a surrogate marker peptide designated as CFTR01 (NSILTETLH

276 ondary adjuvant treatment and the subsequent surrogate marker potential of DTCs for outcome determina

277 efined resistance mechanisms, which serve as surrogate markers, provides an alternative approach to r

278 en FSR, suggesting applications as direct or surrogate markers, respectively, of hepatic fibrogenesis

279 genes in the peripheral blood can be used as surrogate marker(s) for DOX-induced cardiotoxicity.

280 considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation ma

281 e of the improved CSF RT-QuIC is superior to surrogate marker tests for prion diseases such as 14-3-3

282 als of immunotherapy in humans and points to surrogate markers that could be studied in such trials.

283 The aim of this study was to identify surrogate markers that distinguish between systemic infl

284 hosphoinositide cycle and has CNS effects on surrogate markers that may be relevant to the treatment

285 erefore, MRD quantification might serve as a surrogate marker to assess treatment efficacy in randomi

286 high frequency oscillations can be used as a surrogate marker to distinguish the core seizure territo

287 erase chain reaction can be used as a timely surrogate marker to evaluate the appropriateness of anti

288 reated a GFP knockin mouse and used GFP as a surrogate marker to examine C5aR expression.

289 ction of such substitutions would serve as a surrogate marker to identify resistant isolates.

290 the presence of capsid often being used as a surrogate marker to indicate the occurrence of viral rep

291 cCEST MRI signal can be used as a label-free surrogate marker to non-invasively assess mucin glycosyl

292 Anidulafungin can accurately serve as a surrogate marker to predict S and R of Candida to caspof

293 ressed the application of anidulafungin as a surrogate marker to predict the susceptibility of Candid

294 ues, we evaluated the use of micafungin as a surrogate marker to predict the susceptibility of Candid

295 t in childhood, there is a critical need for surrogate markers to best assess, predict, and treat the

296 or monitoring disease progression and act as surrogate markers to identify underlying disease process

297 ole or voriconazole MIC results may serve as surrogate markers to predict the susceptibility of Candi

298 Very few surrogate markers were found to predict technical perfor

299 r the identification of treatment-associated surrogate markers, which may be provided by neuroimaging

300 is quest, the development of more and better surrogate markers will be critical.